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Abstract
Despite substantial progress in the study of diabetes, important questions remain about its
comorbidities and clinical heterogeneity. To explore these issues, we develop a framework
allowing for the first time to quantify nation-wide risks and their age- and sex-dependence
for each diabetic comorbidity, and whether the association may be consequential or causal,
in a sample of almost two million patients. This study is equivalent to nearly 40,000 single
clinical measurements. We confirm the highly controversial relation of increased risk for
Parkinson’s disease in diabetics, using a 10 times larger cohort than previous studies on
this relation. Detection of type 1 diabetes leads detection of depressions, whereas there is a
strong comorbidity relation between type 2 diabetes and schizophrenia, suggesting similar
pathogenic or medication-related mechanisms. We find significant sex differences in the
progression of, for instance, sleep disorders and congestive heart failure in diabetic pa-
tients. Hypertension is a highly sex-sensitive comorbidity with females being at lower risk
during fertile age, but at higher risk otherwise. These results may be useful to improve
screening practices in the general population. Clinical management of diabetes must ad-
dress age- and sex-dependence of multiple comorbid conditions.
Author Summary
We quantify for the first time age- and gender-dependent relative risks for each possible
comorbidity of type 1 and 2 diabetes in a nation-wide claims dataset containing almost
two million patients, and test whether the association may be consequential or causal. This
study therefore contains almost 40,000 single clinical measurements, all with the maxi-
mum patient number available in an entire country. We confirm the relation between dia-
betes and Parkinson's disease, and find different progression routes of mental disorders in
type 1 and type 2 diabetics. Among many other results, we also report significant gender
differences in the progression of congestive heart failure, sleep disorders, hypertension,
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and hyperlipidemia. This work provides the first complete statistical description of all dia-
betic comorbidities and their dependence on patient age and sex. These results may be of
immediate use to improve screening practices and therapy of diabetic patients due to more
accurate diagnosis and treatment of important comorbidities.
Introduction
Diabetes is a global pandemic disease. The world-wide number of adult diabetes patients dou-
bled over the last three decades to approximately 350 million as of 2010, and is expected to
double again until 2030 as a result of population ageing and a shift to western lifestyle patterns
in developing countries [1]. Diabetes comprises a heterogeneous group of disorders with the
most prominent types being type 1 (DM1) and 2 diabetes (DM2). These disorders have differ-
ent pathophysiology and phenotype; the exact underlying mechanisms, their interplay finally
leading to manifestation, progressions of the diseases, and their complications are still unclear.
Diabetes is related to a large number of comorbid diseases, including but not limited to vascu-
lar complications [2], renal failures [2], neuropathy [2], heart diseases [3, 4], cognitive disor-
ders [5, 6], retinopathy [7], and hypertension [8]. Each of these comorbidities opens up a
unique direction of research. Following the methodological approach developed in this work,
thousands of such relations can be investigated in parallel. Besides studying the individual dia-
betic comorbidities and how they depend on patient age and gender, this allows to compare the
strength of these relations among each other and to rank them according to their significance.
Nation-wide collections of physician and hospital claims data allow to explore the health
state of an entire country’s population with unprecedented precision and scale [9]. To exploit
the full potential of ‘big data’ for medical sciences the development of novel, quantitative meth-
ods to extract clinically relevant features from large datasets of electronic health records (EHR)
is necessary. First efforts in this direction have proven to be extremely fruitful by developing or
improving data-driven comorbidity indices to predict mortality rates [10], or by studying
healthcare utilization and outcome measures of specific patient cohorts [11]. Large-scale analy-
ses of comorbidities using EHR data have demonstrated that human disease phenotypes can be
related to each other in highly connected networks with strong pairwise correlations between
diseases [12, 13, 14, 15]. In this work we develop a new quantitative framework to measure
age- and gender-dependent relative risks for all possible comorbidity relations for DM1 and
DM2 using medical claims data from almost two million people. We introduce tests to assess
the significance of the comorbidity relations, the influence of sex, and whether diabetes is more
likely to be a diagnosed before or after the other disease.
Materials and Methods
Data
A research database of the Main Association of Austrian Social Security Institutions containing
pseudonymised claims data of all persons receiving care in Austria between January 1st, 2006
and December 31st, 2007 is used [16]. The data gives a comprehensive, nation-wide picture of
the medical condition of most of the approximately 8.3 million Austrians. The patient collec-
tive was formed by extracting all persons receiving inpatient care in 2006 or 2007. We identi-
fied patients being diagnosed with DM1 or DM2 (ICD10 codes E10 and E11). Patients who
died in 2006 or 2007 were removed. In this way 16 667 DM1 patients (8 355 males and 8 312 fe-
males) and 105 904 with DM2 (50 596 males and 55 308 females) were selected. The total
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sample of inpatients used in this study consists of 1 862 258 patients (1 064 952 females and
797 306 males). From these patients we know their year of birth, sex, ATC codes of all their
prescriptions, and the ICD codes of all their diagnoses (main- and side-diagnoses).
Co-occurrence analysis/ relative risks for comorbidities. For the occurrences of each diag-
nosis x (ICD10, three-digit-level) a patient-age-resolved cross tabulation with the occurrences of
DM1 and DM2 is performed. Symptoms, injuries, pregnancies, and external causes and factors
of morbidity were excluded. We therefore test 1 051 diagnosis (ICD10 codes ranging from A01
to N99) for their co-occurrence with diabetes. The patients are grouped by their age in five-year
intervals and by their gender. Patients older than 95 have been excluded. We test 1 051 possible
comorbidities for 19 age groups for DM1 and DM2, giving 39 938 tests. For each diagnosis and
age interval a contingency table is built. If each entry in the table is greater than 10, relative risks
RR1(2)(x,t) are computed, a chi-squared test is performed and p-values are calculated for reject-
ing the null hypothesis that co-occurrence of the diagnosis with DM1 or DM2 is independent.
This leads to a multiple hypothesis testing problem for each age group where 1 051 hypotheses
are tested in parallel. To correct for these multiple comparisons we apply the Benjamini-Hoch-
berg procedure [17] to control for the false discovery rate α. This procedure is a multiple com-
parison correction where the value of α gives the expected probability that a null hypothesis is
incorrectly rejected. For example, if 100 comorbidities are identified with a false discovery rate α
of α = 0.01, the expected number of false positives among these comorbidities is one. If there are
less than ten co-occurrences or the results are not significant, the relative risk is set to one. For
the co-occurrence analysis we use both the main and the side diagnoses of each patient.
Table 1. A list of major well-known diabetic comorbidities that is used to validate the results of the
co-occurrence analysis.
ICD10 Diagnosis
G45 Transient cerebral ischemic attacks and related syndromes
I10 Essential (primary) hypertension
I20 Angina pectoris
I21 ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction
I24 Other acute ischemic heart diseases
I47 Paroxysmal tachycardia
I50 Heart failure
I60 Nontraumatic subarachnoid hemorrhage
I61 Nontraumatic intracerebral hemorrhage
I62 Other and unspeciﬁed nontraumatic intracranial hemorrhage
I65 Occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction
I66 Occlusion and stenosis of cerebral arteries, not resulting in cerebral infarction
I67 Other cerebrovascular diseases
I70 Atherosclerosis
I71 Aortic aneurysm and dissection
I72 Other aneurysm
I73 Other peripheral vascular diseases
I74 Arterial embolism and thrombosis
M86 Osteomyelitis
N17 Acute kidney failure
N18 Chronic kidney disease
N19 Unspeciﬁed kidney failure
doi:10.1371/journal.pcbi.1004125.t001
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Validation of the co-occurrence analysis. To validate the results of the co-occurrence anal-
ysis we compile a list of major known diabetic complications from different literature sources
[18, 19, 20]. These lists are based on hand curated collections of diabetic comorbidities, some
of them validated using EHR data [19, 20]. These studies disagree on the exact list of ICD
codes for diabetic complications, but each list focusses on cardiovascular, renal, and ophthal-
mic comorbidities. The ICD codes that are listed as diabetic complications in each of these
studies are therefore used to validate our co-occurrence analysis, see Table 1. Note that, for ex-
ample, mental disorders like depression or pancreatic cancer, both well-known diabetic comor-
bidities [5, 6, 21], are not included in any of these studies. Nevertheless, a valid method to
detect comorbidities is supposed to pick up a substantial number of the diagnoses listed in
Table 1, among other comorbidities. We will therefore be interested in the recall R(α) as a func-
tion of the false discovery rate α. R(α) is the probability that a diabetic comorbidity listed in
Table 1 is also identified by our co-occurrence analysis at a given level of α.
Sex ratio. The sex ratio SR(x,t) is related to the quotient of the percentage of female and
male diabetes patients in age group t that also have diagnoses x or are prescribed a medication
x. Denote the number of male (female) DM1 and DM2 patients in age group t by Dm(f)(t) and
the number of male (female) diabetes patients who also have diagnoses or medication x by
Dm(f)(x,t). The sex ratio SR(x,t) is then related to the logarithmic quotient of the percentage of
female and male diabetes patients who also have diagnoses x,
SR x; tð Þ ¼ log
1þ Df ðtÞ
Df ðx;tÞ
1þ DmðtÞ
Dmðx;tÞ
2
4
3
5: ð1Þ
A value of SR(x,t) that is close to zero indicates that the co-occurrence of the diagnosis or medi-
cation x with diabetes is equally likely for males and females. Positive (negative) values of
SR(x,t) indicate that the co-occurrence is more likely for females (males). To assert the statistical
signiﬁcance of nonzero SR(x,t) values we build a contingency table for all diabetes patients of a
given age group t. The table contains the two variables sex and co-occurrence with diagnosis/
medication x. If the null hypothesis of statistical independence of these two variables cannot be
rejected in a chi-squared test using a p-value of p = 0.05 the sex ratio is set to zero, SR(x,t) = 0.
Lead/lag indicator. The lead/lag indicators assess whether patients with diagnoses di are
more likely to be later diagnosed with another disease x, the lead indicator Ilead(di,x), or whether
it is more likely that people having diagnoses x will be diagnosed with diabetes, the lag indicator
Ilag(di,x). There exist several known biases in EHR data that need to be addressed in the definition
of these indicators [22]. (i) The first occurrence of a coding of a diagnosis in the EHR data will
typically not correspond to the true initial diagnosis of the disease. (ii) The data only spans two
years, which may not be enough to observe the manifestation of diabetic complications directly.
We use the following methodology to measure the lead/lag indicators and adjust for these
known biases. Let us consider the lead indicator Ilead(di,x) that measures if the diagnosis x is typ-
ically made after the diabetes diagnosis. Given the limitations of our data, we cannot observe the
typical time between the manifestations of the two diseases. We can, however, measure whether
there is a tendency that x will be diagnosed in a patient that already had a prior diabetes diagno-
sis. As opposed to the co-occurrence analysis, it is crucial for the lead/lag analysis to distinguish
between main- and side diagnoses. To this end we consider the probability that a male (female)
patient has a diabetes diagnosis (main or side diagnosis) in year t1, and a main-diagnosis x in
year t2, but no diagnosis of x in t1 (main or side diagnosis). Denote this probability by pm(f)(x,t2|
di, ¬x,t1) for males (females). This number over-estimates the true effect size, since some cases
where a patient does not have diagnosis x in year t1 might be due to inaccuracies in the coding
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or incompleteness of the data, in particular with respect to unknown pre-existing conditions.
However, we assume that these errors are not systematic in the sense that they are equally likely
to influence the data for year t1 and t2. If there is no true temporal ordering in the onsets of di
and x, the value of pm(f)(x,t2|di, ¬x,t1) just measures noise due to incomplete or inaccurate data.
But this is equally true for the probability that diagnosis x does not occur for a patient in year t2,
given that she(he) has both diagnosis di and x in t1, the probability pm(f)(x,t1|di, ¬x,t2). If there is
a substantial tendency that x is diagnosed after the onset of di, however, these two probabilities
are likely to differ. The lead indicator Ilead(di,x) is therefore given by
Ileadðdi; xÞ ¼ pðx; t2jdi;:x; t1Þ  pðx; t1jdi;:x; t2Þ: ð2Þ
The lag indicator Ilag(di,x) is constructed in analogy to the lead indicator Ilead(di,x) and by ex-
changing the roles of di and x,
Ilagðdi; xÞ ¼ pðdi; t2j:di; x; t1Þ  pðdi; t1j:di; x; t2Þ: ð3Þ
If the frequency of the diagnosis x itself is very small already a very small number of events
might lead to comparably large indicator values for Ilead(di,x) and Ilag(di,x). We therefore exclude
diagnoses x from the analysis if they have less than a threshold of zmale or female patients that
also have di in t2. In the following we set t1 = 2006 and t2 = 2007. For the lag indicator for DM1
we exclude all patients older than 30.
Finally, a statistical test is developed to assess the significance of positive values for Ilead(di,x)
and Ilag(di,x). Surrogate data is created by keeping the list of diagnoses for each patient fixed
and by shuffling the information about the year when the diagnoses were made. Assume that
patient p has np diagnosis {xi} made in the years {τi} with i 2 {1,. . ., np}. The surrogate data is
constructed by replacing {τi} by a random permutation of itself. This procedure is repeated
1 000 times and the lead and lag indicators are computed for each surrogate dataset. We test
the null hypothesis that the values for the lead and lag indicators observed in the data are as
large as one would expect for indicator values taken from the surrogate data, where the tempo-
ral information has been randomly shuffled. The p-value for each lead and lag indicator is the
probability of obtaining the observed values for Ilead(di,x) and Ilag(di,x) from the surrogate data.
The null hypothesis is rejected if p<0.01, that is if out of 1 000 surrogate datasets less than ten
give indicator values that are larger than the observed values.
A significant value of the lead indicator Ilead(di,x) suggests that the incidence of disease x is
more likely in patients with pre-existing diabetes compared to the incidence of diabetes in pa-
tients with pre-existing disease x. A significant value of the lag indicator Ilag(di,x), on the other
hand, suggests that diabetes is typically incident in patients already diagnosed with x. A similar
approach to study lead/lag behavior between diseases, but without a test for statistical signifi-
cance of the results, was proposed for networks of comorbid diseases [12].
Results/Discussion
Fig. 1(a) shows the fraction of male and female inpatients of the entire population as a function
of age. The inpatient fractions are around 20% for children under five, then drop to 10–15%
for ages around ten, and from then on rise to more than 80% for 80 year-old patients, with an
additional peak for females of age around 30, most likely due to child birth. With increasing pa-
tient age the inpatient sample becomes increasingly representative of the entire population.
Fig. 1(b) shows the fraction of male and female DM1 inpatients as a function of age. The distri-
butions have a first peak around the typical onset-age of ten for both male and females, and a
second peak for ages 60 (70) for males (females). Fig. 1(c) shows the fractions of inpatients
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diagnosed with DM2 as a function of age, with comparably few patients below age thirty, and
the bulk of male (female) patients concentrated around age 60 (70).
Fig. 1 shows the sex ratio SR(x,t) for DM1 patients and their number of diagnoses (d) and
received drugs (e); (f) and (g) show the same for DM2 patients. Up to an age of 60 there is an
excess of male patients, for older patients there is an excess of females. For drugs there is a male
excess only for age up to 60 and for less than 10–20 drugs. For older age and a larger number of
drugs there is an excess of female patients. Females below age 60 have fewer diagnoses than
males, but especially those with a large number of diagnoses have more prescriptions than
males. After age 60, females outweigh males in both diagnoses and prescriptions.
The sex ratios for selected groups of medications are shown in Fig. 2. Drugs are classified ac-
cording to their 3-digit-level ATC codes. The sex ratios for drugs for pain relief, psycholeptics,
and psychoanaleptics (N02, N05, N06), but also for diuretics (C03) are dominated by females
at all ages. Beta blocking agents (C07), calcium channel blocker (C08), and ACE inhibitors
(C09) show an excess of males at ages around 30, but a female excess at older ages. Lipid modi-
fying agents (C10) show an excess of males, whereas the gender ratios for antineoplastic agents
(L01) are almost balanced.
Each diagnosis where the null hypothesis of statistical independence with either DM1 or
DM2 can be rejected with a given value of the false discovery rate in at least one of the age
groups is identified as a comorbidity. The results of the co-occurrence analysis are validated by
considering the recall R(α) for the major diabetic comorbidities from Table 1. A false discovery
rate of α = 0.001 gives a list of 75 significant comorbidities and a recall of R(α = 0.001) = 0.59.
Fig 1. The fraction of inpatients in the entire population as a function of age is similar in males and females, except for an excess of females at the
age around 30, most likely related to giving birth (a). After a peak in early childhood, the fraction of inpatients increases to levels of above 80% in older
age. The bulk of male (female) (b) DM1 and (c) DM2 patients is aged around 60 (70), for DM1 patients there is a second peak around age 10. The sex ratio
SR(y,t) is shown for DM1 (d,e) and DM2 (f,g) patients and the number of their diagnoses (d,f) and their prescriptions (e,g). For patients younger than 60, with a
comparably high number of comorbidities, female patients have less diagnoses but take more drugs than males.
doi:10.1371/journal.pcbi.1004125.g001
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For α = 0.01 we retrieve 123 comorbidities with recall R(α = 0.01) = 0.73, and for α = 0.1 we get
297 comorbidities with recall R(α = 0.1) = 1. In the following we choose a threshold of α = 0.01.
The expected number of false positives among these comorbidities is 1.23. Note that for this
threshold we pick up several diseases that are very closely related to those major diabetic com-
plications that we do not retrieve. For example, we do not pick up the subarachnoid, intracere-
bral, and intracranial hemorrhages (I60-I62), but we retrieve cerebral infarctions (I63) and
other strokes (I64). Similarly at this threshold we do not retrieve aneurysms (I71–72), but
artherosclerosis and other peripheral vascular diseases (I70, I73). We identify occlusion and
stenosis of cerebral arteries (I66) instead of precerebral arteries (I65).
The results are summarized in Fig. 3 and Fig. 4, with the left columns showing the DM1 rel-
ative risk RR1(x,t), the middle columns the DM2 relative risk RR2(x,t), and the right columns
the sex ratio SR(x,t). The comorbidities are also listed in the supplement, S1 Table, along with
relative risks, p-values, and patient ages for the age group with the smallest p-values for DM1
and DM2, respectively. In the following we refer to these values whenever referring to the rela-
tive risks of a diagnosis with a 95% confidence interval (CI).
Lead/lag behavior is identified for male and female DM1 and DM2 patients if the null hy-
pothesis that the observed indicator values for Ilead(di,x) and Ilag(di,x) can be obtained from
randomized surrogate data can be rejected with a p-value of p<0.01. The threshold z is set to z
= 50 for DM1 and DM2. Table 2 shows diagnoses which have been identified as either leading
or lagging for male or female DM1 or DM2 patients.
In the following we discuss results for individual comorbidities. Emphasis is put on comor-
bidities that have been disputed in the literature, or where the lead/lag analysis advances our
understanding of them. Another important group of results consists of comorbidities for
which we find a yet unknown degree of sensitivity to sex. In particular we find for several co-
morbidities a certain patient age where the sex ratio switches from an excess of one sex to an
excess of the different sex for older ages; we will refer to these patient ages as ‘age switch’.
Fig 2. Sex ratios for the numbers of prescriptions of selected therapies on 3-digit-level ATC codes.Results for medications related to pain relief,
psycholeptics, and psychoanaleptics (N02, N05, N06) and diuretics (C03) are dominated by females at all ages. Beta blocking agents (C07), calcium channel
blocker (C08), and ACE inhibitors (C09) show an excess of males at ages around 30, but a female excess at older ages. Lipid modifying agents (C10) show
an excess of males, the sex ratio for antineoplastic agents (L01) is almost balanced.
doi:10.1371/journal.pcbi.1004125.g002
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Fig 3. Relative risks for DM1 (left column) and DM2 (middle column) patients, and sex ratios (right column) for core comorbidities using a false
discovery rate of α<0.01 and an ICD code from the range A01-I27.Color encodes the values of the risks and sex ratios.
doi:10.1371/journal.pcbi.1004125.g003
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Fig 4. Relative risks for DM1 (left column) and DM2 (middle column) patients, and sex ratios (right column) for core comorbidities using a false
discovery rate of α<0.01 and an ICD code from the range I34-N99.Color encodes the values of the risks and sex ratios.
doi:10.1371/journal.pcbi.1004125.g004
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Controversial comorbidity associations
Parkinson’s disease. In the literature there is no consensus on whether diabetes patients have a
higher risk for Parkinson’s disease (PD), or if there is actually a lower risk or no relation at all.
There are two large prospective studies finding an increased risk for PD in diabetes patients,
one study finding no relation, and one study reporting lower risk of diabetes [23]. We find that
PD is comorbid (2.3, CI 1.9–2.7 for DM1 and 1.5, CI 1.4–1.6 for DM2) with an excess of male
patients. It has been suggested that surveillance bias may lead to the reporting of spurious posi-
tive correlations between PD and diabetes [23]. Given our patient cohort we can exclude this
kind of bias. Note that the size of our patient cohort (1.8 million patients) is at least 10 times
larger than the largest cohorts in previous studies on the relation between PD and diabetes
[23, 24]. As potential mechanism of this association the involvement of insulin in the regula-
tion of brain dopanergic activity has been proposed [25, 26]. Animal and in vitro studies have
shown that insulin and dopamine may exert reciprocal regulation [26].
Mental disorders.Depression, schizophrenia, and schizo-affective disorders are also comor-
bid. While the relative risks for DM1 patients are highest in the age group 65–70 with values
from 1.9–2.3 for these diseases, we find higher risks for DM2 patients at younger ages, e.g. a rela-
tive risk of 4.8, CI 3.3–7.0, for recurrent depressive disorders at age 35–40. We find that depres-
sion is usually incident in DM1 patients. From these results one may speculate that DM1 patients
develop depressions because of the burden of the disease and the psychological distress of main-
taining a good level of glycemic control. Depression in diabetic patients in general, DM1 and
Table 2. Diagnoses are shown which have been identiﬁed in the lead/lag analysis.
ICD diabetes type sex
Diabetes leads (comes before other disease)
A41 Other sepsis 2 F
C25 Malignant neoplasm of pancreas 2 F
C34 Malignant neoplasm of bronchus and lung 2 M
E16 Other disorders of pancreatic internal secretion 2 M
F03 Unspeciﬁed dementia 2 F
F32 Depressive episode 1 M
G45 Transient cerebral ischemic attacks and related syndromes 1 F
I25 Chronic ischemic heart disease 1 F
I46 Cardiac arrest 2 M+F
I48 Atrial ﬁbrillation and ﬂutter 1 M
I50 Heart failure 1 F
I50 Heart failure 2 M
J18 Pneumonia, unspeciﬁed organism 2 M
L89 Decubitus ulcer 2 M
M48 Other spondylopathies 2 M
N18 Chronic renal failure 2 F
Diabetes lags (comes after other disease)
C44 Other and unspeciﬁed malignant neoplasm of skin 2 M
D40 Neoplasm of uncertain behavior of male genital organs 2 M
K81 Cholecystitis 2 M
For each diagnoses the order (if diabetes leads or lags), gender (‘F’ for females, ‘M’ for males) and
diabetes type (1 or 2) where the relationship was detected are listed.
doi:10.1371/journal.pcbi.1004125.t002
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DM2, is dominated by females [5], so is the association between depression and overweight [27].
Indeed it is remarkable that depression and overweight as diabetic comorbidities show nearly the
same age and sex dependence. A possible biological mechanism is that obesity increases the risk
of increased insulin resistance, which may induce alterations in the brain which in turn increase
the risk of depression [28]. Of importance are also psychological pathways, since the perception
of being overweight increases psychological distress [29]. Diabetes has also been associated with
the use of atypical neuroleptics in the treatment of schizophrenia [30]. The sex ratios for antipsy-
chotics show a strong excess of female patients, see Fig. 2, which compares well with the female
excess in the sex ratios for depression and schizophrenia. It is interesting to note that the comor-
bidity relations with schizophrenia and schizo-affective disorders stand out as much weaker for
DM1 than for DM2 patients, when compared to all other results of the comorbidity analysis.
Gender-specific results on comorbidities
Endocrine and metabolic disorders.While patients with thyroiditis, hypothyroidism, thyro-
toxicosis, and obesity are predominantly female, disorders of the lipoprotein, purine, and py-
rimidine metabolism tend to be found in males. Diabetic patients feature a two to three times
higher increased risk of disorders of the thyroid gland, particularly those with autoimmune dia-
betes, a comorbidity relation that is strongly influenced by gender [31]. For volume depletion
and disorders of fluid, electrolyte and acid-base balance there appears to be an age switch, from
an excess of male patients for ages 20–40 to an excess of females in older age. Primary hyperten-
sion is a comorbidity with relative risks of 5.3 (CI 4.8–5.9) for DM1 and 9.5 (CI 8.8–10) for
DM2. These switches may indicate an important impact of sexual hormones and of potential
pregnancies but may also point to social factors related to sex-specific phases of life. The pre-
scriptions of beta and calcium channel blocker, as well as ACE inhibitor show a sex-dependence
very similar to hypertension, suggesting that these drugs are commonly used to treat hyperten-
sion, see Fig. 2. There is a strong excess of female patients in the prescriptions of diuretics, espe-
cially in elderly patients, whereas there is a strong excess of younger males being prescribed
statins or other lipid modifying agents, the latter matching the sex ratio observed for hypercho-
lesterolemia and hyperlipidemia. Note that our results make no statements about the combina-
tions of antihypertensive drugs which are actually used in the treatment of individual patients.
Infections and sepsis. Bacterial and viral infections (gastroenteritis, erysipelas, pneumonia,
osteomyelitis, hepatitis, dermatophytosis, candidiasis) show an excess of male patients with the
exception of gastroenteritis and candidiasis, which are dominated by female patients. We find
an excess of sepsis comorbidity which is strongest in male DM1 patients at the age around 50,
with higher relative risks for DM1 (12, CI 8.2–18) than DM2 (2.7, CI 2.4–2.9).
Epilepsy. The increased risk for epilepsy (4.6, CI 3.1–6.9, for DM1 and 1.6, CI 1.4–1.7, for
DM2) in young type 1 diabetics [32] may be linked to ketoacidosis as a two times higher risk of
epilepsy was found in children and adolescents with metabolic acidosis [33]. A four times
greater risk of DM1 was also described in young adults with epilepsy [34]. Both metabolic ex-
tremes, hypoglycemia and diabetic ketoacidosis, relate to EEG abnormalities in diabetic chil-
dren which may increase risk of epilepsy.
Congestive heart failure. The Framingham heart study reported that diabetic women are
more vulnerable to congestive heart failure (CHF, RR of 5.2, CI 4.7–5.9, for DM1, 3.8, CI
3.6–3.9, for DM2) than men [35]. However, subsequent cohort studies found no such sex dif-
ferences [35, 36]. We find an excess of male patients and that diabetes is typically detected be-
fore CHF in females with DM1 and in males with DM2.
Sleep disorders. Sleep disorders are comorbid in DM1 (1.9, CI 1.5–2.4) and DM2 patients
(2.3, CI 2.1–2.6). We find support for sex specific progression routes. It is known that DM2
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and obstructive sleep apnea (OSA) present a vicious circle, with OSA exerting adverse effects
on glucose metabolism and thereby increasing the risk for DM2 [37]. In patients with already
existing DM2, on the other hand, there is a significant relationship between sleep-disordered
breathing (SDB) and insulin resistance independent of obesity [38]. The fact that there is an ex-
cess of male patients in the comorbidity relation may be related to the higher prevalence of cen-
tral adiposity and therefore OSA in men [37].
Further comorbidities
Pancreatic cancer. There are higher relative risks for DM1 patients (8.6, CI 5.6–13) than DM2
patients (2.5, CI 2.1–2.8). The risks peak in the age range 50–70 with a balanced sex ratio. It
has been shown that diabetic patients are at increased risk of pancreatic cancer with a pooled
RR of approximately two compared to non-diabetics in a meta-analysis [21] with at least one
year diabetes duration prior to diagnosis of pancreatic cancer [39]. Diabetes also leads the diag-
nosis of pancreatic and lung cancer.
Behavioral and related disorders.Nicotine dependence (3.3, CI 2.7–4.1, for DM1 and 2.8,
CI 2.6–3.0, for DM2) and alcohol related disorders dependence (2.3, CI 1.7–3.2 and 2.1, CI
1.9–2.4) are comorbidities with relative risks peaking at ages 30–45, dominated by male patients.
Alcoholic liver disease dependence (4.0, CI 2.7–5.7 and 2.6, CI 2.3–2.9) is also a male-dominated
comorbidity. Toxic liver disease (2.8, CI 1.6–4.9 and 14, CI 8.5–23) and fibrosis and cirrhosis of
liver (5.0, CI 3.7–6.6 and 2.4, CI 2.2–2.7) show also an excess of male patients. There tend to be
higher risks for DM1 than DM2 patients, potentially outlining greater impact of chronic hyper-
glycemia than of overweight-related parameters of the metabolic syndrome. The relationship
between alcohol consumption and DM2 has been shown to be dosage dependent. While moder-
ate alcohol consumption is protective, dosages of more than 60g/day increase diabetes risk [40].
It is not possible to establish an alcohol-dosage dependent diabetes risk from our data.
Cardiovascular diseases. Identified comorbid diseases of the circulatory system include is-
chemic and pulmonary heart disease, cardiomyopathy, valvular disorders, tachycardia, as well
as cerebrovascular diseases and diseases of the arteries and veins [2, 4, 41]. Comorbid diseases
of the circulatory system show a consistent excess of male patients, including ischemic, pulmo-
nary, and other heart diseases (cardiomyopathy, valvular disorders, tachycardia), as well as ce-
rebrovascular diseases and diseases of the arteries and veins. The highest relative risks among
cardiovascular diseases are found for acute ischemic heart diseases for DM1 patients (6.6,
CI 5.2–8.3, compared to 3.1, CI 2.8–3.4, for DM2 patients) at ages higher than 60.
Pulmonary diseases. Pneumonia and acute bronchitis show increased relative risks for
older ages (e.g. for pneumonia 2.7, CI 2.4–3.0, for DM1, 2.3, CI 2.1–2.4, for DM2). Chronic ob-
structive pulmonary disease (COPD) is led by diabetes (2.9, CI 2.5–3.5 and 2.2, CI 2.1–2.3). Di-
abetes is often identified as independent risk factor for lower respiratory tract infections [42].
Individuals with COPD are substantially more likely to have pre-existing DM [43], on the
other hand lung function impairment in COPD is a risk factor for developing diabetes and in-
sulin resistance [44]. Benign pleural effusion (3.4, CI 2.1–5.6 and 3.1, CI 2.5–3.9), representing
a symptom of various underlying diseases, is dominated by males. In diabetic patients pleural
effusion may be related to left ventricular dysfunction as described previously [45].
Other comorbidities. Iron-deficiency and anemia in chronic diseases show higher relative
risks for DM1 (3.7, CI 3.0–4.6, and 6.3, CI 4.9–8.1) than DM2 (2.7, CI 2.4–2.9 and 2.8, CI
2.5–3.2) patients. Cataracts, retinal detachments, glaucoma, disorders of the vitreous body, and
blindness are identified here with relative risks up to 200. The higher relative risks for DM1
compared to DM2 patients for retinopathies [7] at older age suggest a higher lifespan for type 1
diabetics. Chronic and acute kidney diseases, the nephrotic syndrome, and glomerular
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disorders are identified as comorbidities with an excess of male patients; relative risks range up
to 128 for DM1 patients and 8.6 for DM2. There is an excess of female patients in the age range
20–40. Intestinal malabsorption (including celiac disease) shows elevated risks for ages 10–25
for DM1 (10, CI 6.3–17) with a weak female excess; there are no significant results for DM2.
Cholelithiasis is a female dominated comorbidity (1.7, CI 1.5–2.0 and 1.5, CI 1.4–1.6). Chole-
cystitis is typically followed by DM2 in males. Pressure and non-pressure ulcers exhibit higher
risks for DM1 (7.2, CI 5.2–9.9, and 7.4, CI 5.8–9.4) than DM2 patients (2.2, CI 2.0–2.4 and 4.2,
CI 3.9–4.6). For males there are increased risks for disorders of prepuce (6.0, CI 3.5–10 and 3.1,
CI 2.5–3.8), while for females there is increased risk for disorders of the urinary system (2.5, CI
2.2–2.8 and 1.8, CI 1.7–1.9). Evidence from epidemiological studies suggests that asymptomatic
bacteriuria and symptomatic urinary tract infections occur more commonly in women with
DM compared to non-diabetic controls [41, 46]. Increased prevalence of urinary incontinence
and urge incontinence among women with DM2 [47, 48] has been reported.
Limitations. Only persons with inpatient stays were included in the study. To test if this
pre-selection introduces a bias in our results, we repeated the study with a sample of all patients
having been prescribed at least once a drug used in diabetes (ATC code starting with ‘A10’) in
2006 or 2007. We compare the frequencies of their diseases with those in the rest of the popula-
tion, roughly 8.3 million patients. This assumes that DM patients with no hospital stay in the
study period have no diagnosis and therefore no comorbidities. Although this is a highly incor-
rect assumption, it serves as a conservative test-assumption, which allows to test if the comor-
bidities are simply significant as a consequence of our limited sample that contains only
inpatients. Results are shown in the supplement in S1 Fig. In the enlarged sample only one out
of the 123 comorbidities using the inpatient sample has a p-value greater than 0.05 (M23), all
other remain significant (p<0.05). Significance of comorbidity in the inpatient sample is there-
fore highly representative of comorbidity in the entire population. However, our approach
might miss diabetic comorbidities that are typically not related to hospitalizations and that are
most prevalent in younger patients, where the inpatient sample contains a lesser amount of the
entire population, compare Fig. 1(a). Unknown pre-existing conditions may also affect the ob-
served temporal order of the diseases, which has been addressed by applying a series of correc-
tions to the lead/lag indicators, equations (2) and (3). Other limitations relate to the coding
quality of disorders in the medical claims data, which has been shown to lead to an under-
reporting of comorbidities [49] and may cause false negatives in our testing procedure.
This work shows the enormous potential that large-scale analyses of EHR data offer for the
medical sciences. For the first time we develop a standardized testing procedure to obtain a com-
plete comorbidity profile for DM1 and DM2 using medical claims data. This analysis is equiva-
lent to 39 938 individual tests, each with the maximum number of patients available in a
country. We identified 123 highly significant disorders with increased or decreased risks, strong-
ly depending on patient age and sex. The comorbidities are investigated by a lead/lag analysis to
inquire whether the relation between the diseases is more likely causal or consequential.
Taken together, these results underscore that there is a substantial number of disorders that
are related to diabetes, besides the well-known long-term complications. Diabetic comorbidi-
ties are rule rather than exception and their treatment must address their high degree of age
and sex dependence. Despite being a risk factor for certain diabetic complications, sex may also
influence and to a certain degree even determine the mechanisms underlying the disease pro-
gressions. Our results may be of immediate use to improve screening practices and therapy of
diabetic patients to increase their quality of life and potentially contribute to longer life expec-
tancy due to early detection and treatment of important comorbidities. In particular we pro-
pose to screen and, where applicable, treat diabetes patients for comorbid depressions, since
this allows a more efficient treatment of diabetes itself. Depressive patients should be screened
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for diabetes to detect it at an early stage and perform lifestyle interventions that focus on weight
control. It is also important to treat depressive patients with drugs that have a minimum of
side effects on weight gain, and lipid and glucose metabolism. Our results emphasize that phy-
sicians must be aware of non-traditional diabetic comorbidities and risk factors during anam-
nesis and that, for example, screening for diabetes may be appropriate in patients with
cardiovascular diseases, CHF, or fatty liver, whereas diabetes patients should be screened for
pancreatic cancer.
Supporting Information
S1 Fig. The values for relative risks (left panels) and sex ratios (right panels) for the 123
identified comorbidities are computed using a patient sample of all persons receiving a
drug used in diabetes (ATC code A10). The results from the inpatient sample are reproduced
to large parts, only disorder M23 exhibits non-significant p-values.
(TIF)
S1 Table. ICD code and disease name for the 123 comorbidities identified in the co-occur-
rence analysis. For the age groups with the smallest p-value the relative risks RR, patient ages,
and the corresponding p-values are shown for DM1 and DM2, respectively. Where the patient
sample was too small to apply the statistical tests missing values are shown.
(PDF)
S1 Data. Comorbidity data for DM1 patients, the relative risks RR1, the confidence inter-
vals for RR1, if applicable the p-value for the co-occurrence analysis, and the sex ratio for
each diagnosis and age group.
(CSV)
S2 Data. Comorbidity data for DM2 patients, the relative risks RR2, the confidence inter-
vals for RR2, if applicable the p-value for the co-occurrence analysis, and the sex ratio for
each diagnosis and age group.
(CSV)
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